Recent Advances in Pyrazole-based Protein Kinase Inhibitors as Emerging Therapeutic Targets

被引:0
|
作者
Cetin, Adnan [1 ]
机构
[1] Van Yuzuncu Yil Univ, Fac Educ, Dept Chem, TR-65080 Van, Turkiye
关键词
Cancer; drug discovery; pharmacology; spectroscopy; pyrazole-based protein kinase inhibitors; therapeutic targets; PATENT CITATIONS; SERINE-PROTEASE; POTENT; AGENTS; EGFR;
D O I
10.2174/0113862073252211231024182817
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background Pyrazole-scaffold protein kinase inhibitors (PKIs) have emerged as promising therapeutic agents for the treatment of various diseases, such as cancer, inflammatory disorders, and neurological diseases. This review article provides an overview of the pharmacological properties of pyrazole-scaffold PKIs, including their mechanism of action, selectivity, potency, and toxicity. The article also summarizes the recent developments in the design and synthesis of pyrazole-scaffold PKIs, highlighting the structural features and modifications that contribute to their pharmacological activity. In addition, the article discusses the preclinical and clinical studies of pyrazole-scaffold PKIs, including their efficacy, safety, and pharmacokinetic properties.Methods A comprehensive search has been conducted on several online patent databases, including the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the World Intellectual Property Organization (WIPO). The search was conducted using pyrazole as the keyword. The search was limited to patents filed between 2015 and 2022. Patents were included if they involved articles in the fields of protein kinase inhibitors, and included literature on some pyrazoles and their pharmacological activities.Results Data were extracted from each included patent on the following variables: patent title, patent number, inventors, assignee, filing date, publication date, patent type, and field of invention. Data were extracted from each patent using a standardized form to ensure consistency and accuracy.Conclusion The design and pharmacological evaluation of organic compounds containing pyrazole structure as biologically active substances have been done, and the key structures from the pharmacological data obtained as protein kinase inhibitors have been addressed in detail. The review concludes with a discussion on the current challenges and future directions for the development of pyrazole-scaffold PKIs as therapeutic agents. Overall, this review article provides a comprehensive summary of the pharmacological properties of pyrazole-scaffold PKIs, which will be of interest to researchers and clinicians in the field of drug discovery and development.
引用
收藏
页码:2791 / 2804
页数:14
相关论文
共 50 条
  • [1] Recent advances in the synthesis and medicinal perspective of pyrazole-based α-amylase inhibitors as antidiabetic agents
    Khator, Rakesh
    Monga, Vikramdeep
    FUTURE MEDICINAL CHEMISTRY, 2024, 16 (02)
  • [2] Potent and selective pyrazole-based inhibitors of B-Raf kinase
    Hansen, Joshua D.
    Grina, Jonas
    Newhouse, Brad
    Welch, Mike
    Topalov, George
    Littman, Nicole
    Callejo, Michele
    Gloor, Susan
    Martinson, Matthew
    Laird, Ellen
    Brandhuber, Barbara J.
    Vigers, Guy
    Morales, Tony
    Woessner, Rich
    Randolph, Nikole
    Lyssikatos, Joseph
    Olivero, Alan
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (16) : 4692 - 4695
  • [3] Therapeutic targets and recent advances in protein immunotoxins
    Madhumathi, J.
    Verma, Rama S.
    CURRENT OPINION IN MICROBIOLOGY, 2012, 15 (03) : 300 - 309
  • [4] Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase
    Graneto, Matthew J.
    Kurumbail, Ravi G.
    Vazquez, Michael L.
    Shieh, Huey-Sheng
    Pawlitz, Jennifer L.
    Williams, Jennifer M.
    Stallings, William C.
    Geng, Lifeng
    Naraian, Ashok S.
    Koszyk, Francis J.
    Stealey, Michael A.
    Xu, Xiangdong D.
    Weier, Richard M.
    Hanson, Gunnar J.
    Mourey, Robert J.
    Compton, Robert P.
    Mnich, Stephen J.
    Anderson, Gary D.
    Monahan, Joseph B.
    Devraj, Rajesh
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (23) : 5712 - 5719
  • [5] Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2
    Amrhein, Jennifer A.
    Wang, Guiqun
    Berger, Benedict-Tilman
    Berger, Lena M.
    Kalampaliki, Amalia D.
    Kraemer, Andreas
    Knapp, Stefan
    Hanke, Thomas
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (06): : 833 - 840
  • [6] Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors
    Sawyer, TK
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (01) : 1 - 19
  • [7] Pyrazole-based cathepsin S inhibitors with improved cellular potency
    Wei, Jianmei
    Pio, Barbara A.
    Cai, Hui
    Meduna, Steven P.
    Sun, Siquan
    Gu, Yin
    Jiang, Wen
    Thurmond, Robin L.
    Karlsson, Lars
    Edwards, James P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (20) : 5525 - 5528
  • [8] The development of new bicyclic pyrazole-based cytokine synthesis inhibitors
    Townes, JA
    Golebiowski, A
    Clark, MP
    Laufersweiler, MJ
    Brugel, TA
    Sabat, M
    Bookland, RG
    Laughlin, SK
    VanRens, JC
    De, BS
    Hsieh, LC
    Xu, SC
    Janusz, MJ
    Walter, RL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (19) : 4945 - 4948
  • [9] Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors
    Shi, Qiang
    Yang, Xi
    Ren, Lijun
    Mattes, William B.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (03) : 217 - 226
  • [10] Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges
    Ling, Yuan
    Zhang, Zikang
    Zhang, Hua
    Huang, Zunnan
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (29) : 4303 - 4310